AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|
21.2 C
New York
Wednesday, July 29, 2026

Tag: bone

newssourceFORcompanyinformationcontent1releasesmarket

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

U.S. Oral Surgery Management Moves into 31st State

U.S. Oral Surgery Management has four new partner practices, including its first in the state of Nebraska.

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

MedTech Manufacturer Juvent Joins the Inc. 5000 List of America’s Fastest-Growing Private Companies

Juvent joins the 2025 Inc. 5000, ranking #757 with 552% growth over 3 years, for its Micro-Impact Platform, which improves mobility, pain, and wellness.

If you purchased any Pork product in the United States from June 28, 2014, through June 30, 2018, for business use in commercial food...

MINNEAPOLIS, Aug. 11, 2025 /PRNewswire/ -- A Settlement has been reached in a class action antitrust lawsuit filed on behalf of Commercial and Institutional...

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron announces the pricing of a public offering of common stock and warrants.

Houston Native Mighty Bolton Drives ‘The Art of Dialogue’ to Global Success with Authentic Storytelling

Houston, TX, Aug. 07, 2025 (GLOBE NEWSWIRE) -- From his hometown of Houston, Texas, Mighty Bolton has built ‘The Art of Dialogue’ into one of today’s leading media brands by staying true to authentic storytelling and compelling conversations. What started as a passion project has quickly become a global phenomenon, captivating millions of viewers with its honest and insightful content.

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBone

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers